Skip to main content
Premium Trial:

Request an Annual Quote

Former Perkin-Elmer COO Launches Discovery Co.

Premium

LA JOLLA, Calif.--A new company launched by Riccardo Pigliucci, former CEO of Life Sciences International and past president and chief operating officer of Perkin-Elmer, claimed it will create a new paradigm for serving the drug discovery needs of pharmaceutical companies. Discovery Partners International says it will form partnerships with pharmaceutical and biotech companies to foster the development of new technologies.

Pigliucci commented, "Most drug discovery platform companies have turned to developing their own lead compounds. We'll maintain our focus on the development of novel drug discovery platforms through funding or acquisition of companies with leading-edge or complementary technologies."

The first businesses brought under Discovery Partners' umbrella are Irori, a combinatorial chemistry company, and ChemRx, a new firm providing primary lead discovery chemical libraries and lead-optimization services using Irori's technology. Platform and service companies focusing on bioinformatics and screening technologies will be added in the near future, Pigliucci asserted.

Filed under

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.